[Catheter-Based Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: Long-Term Follow-Up 1996-2016].

Since the first publication in 1995 percutaneous septal ablation (acronyms in alphabetical order: ASA, ESA, NSMR, PTSMA, TASH, among others) has made its way from a small case series into the international guidelines for patients with HOCM and symptoms not responding to medical treatment. We now report on the long-term course (20 years) in the first 6 cases who were successfully treated in our institution in early 1996, published in this Journal shortly thereafter.

[From cardiovascular prevention to anti-aging medicine: influence on telomere and cell aging].

The most important cardiovascular risk factors (hypercholesterolemia , hypertension, diabetes, chronic stress, physical inactivity, smoking, adipositas) were evaluated in the second half of the last century using placebo controlled trials. The mechanismen of action was not fully understood or remained unclear. In some studies not only the risk of atherosclerosis was reduced but life expectancy was improved.

Beneficial effects of atorvastatin on myocardial regions with initially low vasodilatory capacity at various stages of coronary artery disease.

Purpose: The aim of this study was to analyse non-invasively the regional effect of therapy with an HMG-CoA reductase inhibitor on myocardial blood flow in patients with coronary artery disease (CAD) with special reference to segments with initially substantially impaired vasodilation.

Methods: The study included 26 patients with untreated hypercholesterolaemia. Coronary angiography revealed CAD in nine patients with stenosis >50% and wall irregularities or minimal stenosis <30% in 17 patients.